The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide

Chun Chun Yang, Jiunn Diann Lin, Ko Lin Kuo, Chung Ze Wu, Jer Chuan Li, Yi Jen Hung, Tso Fu Wang, Chien Hsing Lee, Shi Wen Kuo, Dee Pei

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: Sulfonylurea with long half-life such as gliclazide has sustained stimulation on insulin secretion compared to repaglinide which has short half-life for only about 1 h. In this hospital cohort, randomized, cross-over study, we used modified low dose graded glucose infusion test (M-LDGGI) to evaluate second phase insulin secretion after 4 months of treatment with either gliclazide or repaglinide. Methods: Sixteen fresh type 2 diabetes with age of 49.5 ± 2.6 years old and BMI of 25.3 ± 0.9 kg/m2 were included. After titration and maintain dose stage, all cases were randomized to the repaglinide or gliclazide treatment for 4 months. At the end of each treatment period, an M-LDGGI was done. Results: The general linear model repeated measurement was used to evaluate the plasma glucose, insulin and insulin/glucose curve during M-LDGGI. Although the plasma insulin and insulin/glucose ratios were higher at 40 min and 100-120 min, they did not reach statistically significant. The area under curve of the plasma glucose, insulin and insulin/glucose ratio was also used to evaluate the secretory capacity of beta cell. Although the AUC of the ratio of plasma insulin/plasma glucose seems to be more evident than the curves, they are still not significantly different with each other. Conclusions: In conclusion, although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months. Further study with longer duration and larger study cohort are needed to solve this interesting and important question.

Original languageEnglish
Pages (from-to)37-42
Number of pages6
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
Volume1
Issue number1
DOIs
Publication statusPublished - Feb 2007
Externally publishedYes

Fingerprint

repaglinide
Gliclazide
Insulin
Glucose
Area Under Curve
Half-Life

Keywords

  • Gliclazide
  • Insulin secretion
  • Low dose graded glucose infusion test
  • Repaglinide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide. / Yang, Chun Chun; Lin, Jiunn Diann; Kuo, Ko Lin; Wu, Chung Ze; Li, Jer Chuan; Hung, Yi Jen; Wang, Tso Fu; Lee, Chien Hsing; Kuo, Shi Wen; Pei, Dee.

In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 1, No. 1, 02.2007, p. 37-42.

Research output: Contribution to journalArticle

Yang, Chun Chun ; Lin, Jiunn Diann ; Kuo, Ko Lin ; Wu, Chung Ze ; Li, Jer Chuan ; Hung, Yi Jen ; Wang, Tso Fu ; Lee, Chien Hsing ; Kuo, Shi Wen ; Pei, Dee. / The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide. In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2007 ; Vol. 1, No. 1. pp. 37-42.
@article{55daded8dcc643d39c49b0eca096d4a2,
title = "The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide",
abstract = "Aims: Sulfonylurea with long half-life such as gliclazide has sustained stimulation on insulin secretion compared to repaglinide which has short half-life for only about 1 h. In this hospital cohort, randomized, cross-over study, we used modified low dose graded glucose infusion test (M-LDGGI) to evaluate second phase insulin secretion after 4 months of treatment with either gliclazide or repaglinide. Methods: Sixteen fresh type 2 diabetes with age of 49.5 ± 2.6 years old and BMI of 25.3 ± 0.9 kg/m2 were included. After titration and maintain dose stage, all cases were randomized to the repaglinide or gliclazide treatment for 4 months. At the end of each treatment period, an M-LDGGI was done. Results: The general linear model repeated measurement was used to evaluate the plasma glucose, insulin and insulin/glucose curve during M-LDGGI. Although the plasma insulin and insulin/glucose ratios were higher at 40 min and 100-120 min, they did not reach statistically significant. The area under curve of the plasma glucose, insulin and insulin/glucose ratio was also used to evaluate the secretory capacity of beta cell. Although the AUC of the ratio of plasma insulin/plasma glucose seems to be more evident than the curves, they are still not significantly different with each other. Conclusions: In conclusion, although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months. Further study with longer duration and larger study cohort are needed to solve this interesting and important question.",
keywords = "Gliclazide, Insulin secretion, Low dose graded glucose infusion test, Repaglinide",
author = "Yang, {Chun Chun} and Lin, {Jiunn Diann} and Kuo, {Ko Lin} and Wu, {Chung Ze} and Li, {Jer Chuan} and Hung, {Yi Jen} and Wang, {Tso Fu} and Lee, {Chien Hsing} and Kuo, {Shi Wen} and Dee Pei",
year = "2007",
month = "2",
doi = "10.1016/j.dsx.2006.11.006",
language = "English",
volume = "1",
pages = "37--42",
journal = "Diabetes and Metabolic Syndrome: Clinical Research and Reviews",
issn = "1871-4021",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide

AU - Yang, Chun Chun

AU - Lin, Jiunn Diann

AU - Kuo, Ko Lin

AU - Wu, Chung Ze

AU - Li, Jer Chuan

AU - Hung, Yi Jen

AU - Wang, Tso Fu

AU - Lee, Chien Hsing

AU - Kuo, Shi Wen

AU - Pei, Dee

PY - 2007/2

Y1 - 2007/2

N2 - Aims: Sulfonylurea with long half-life such as gliclazide has sustained stimulation on insulin secretion compared to repaglinide which has short half-life for only about 1 h. In this hospital cohort, randomized, cross-over study, we used modified low dose graded glucose infusion test (M-LDGGI) to evaluate second phase insulin secretion after 4 months of treatment with either gliclazide or repaglinide. Methods: Sixteen fresh type 2 diabetes with age of 49.5 ± 2.6 years old and BMI of 25.3 ± 0.9 kg/m2 were included. After titration and maintain dose stage, all cases were randomized to the repaglinide or gliclazide treatment for 4 months. At the end of each treatment period, an M-LDGGI was done. Results: The general linear model repeated measurement was used to evaluate the plasma glucose, insulin and insulin/glucose curve during M-LDGGI. Although the plasma insulin and insulin/glucose ratios were higher at 40 min and 100-120 min, they did not reach statistically significant. The area under curve of the plasma glucose, insulin and insulin/glucose ratio was also used to evaluate the secretory capacity of beta cell. Although the AUC of the ratio of plasma insulin/plasma glucose seems to be more evident than the curves, they are still not significantly different with each other. Conclusions: In conclusion, although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months. Further study with longer duration and larger study cohort are needed to solve this interesting and important question.

AB - Aims: Sulfonylurea with long half-life such as gliclazide has sustained stimulation on insulin secretion compared to repaglinide which has short half-life for only about 1 h. In this hospital cohort, randomized, cross-over study, we used modified low dose graded glucose infusion test (M-LDGGI) to evaluate second phase insulin secretion after 4 months of treatment with either gliclazide or repaglinide. Methods: Sixteen fresh type 2 diabetes with age of 49.5 ± 2.6 years old and BMI of 25.3 ± 0.9 kg/m2 were included. After titration and maintain dose stage, all cases were randomized to the repaglinide or gliclazide treatment for 4 months. At the end of each treatment period, an M-LDGGI was done. Results: The general linear model repeated measurement was used to evaluate the plasma glucose, insulin and insulin/glucose curve during M-LDGGI. Although the plasma insulin and insulin/glucose ratios were higher at 40 min and 100-120 min, they did not reach statistically significant. The area under curve of the plasma glucose, insulin and insulin/glucose ratio was also used to evaluate the secretory capacity of beta cell. Although the AUC of the ratio of plasma insulin/plasma glucose seems to be more evident than the curves, they are still not significantly different with each other. Conclusions: In conclusion, although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months. Further study with longer duration and larger study cohort are needed to solve this interesting and important question.

KW - Gliclazide

KW - Insulin secretion

KW - Low dose graded glucose infusion test

KW - Repaglinide

UR - http://www.scopus.com/inward/record.url?scp=34247846308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247846308&partnerID=8YFLogxK

U2 - 10.1016/j.dsx.2006.11.006

DO - 10.1016/j.dsx.2006.11.006

M3 - Article

AN - SCOPUS:34247846308

VL - 1

SP - 37

EP - 42

JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

SN - 1871-4021

IS - 1

ER -